Grants paid by Rosenau Family Research Foundation
EIN 26-3070514 · Muskego, MN · Form 990-PF, Part XV · NTEE T20
Rosenau Family Research Foundation of Muskego, MN (EIN 26-3070514) reported 47 grants paid totaling $7,309,529 to 18 recipients in tax years 2018–2024, on Form 990-PF, Part XV. It also reported $5,860,623 approved for future payment, which is listed separately and not included in the total. Derived from IRS e-file data, dataset version 2026.09.0, built 2026-09-03.
Grants paid
$7,309,529
47 grants
Recipients
18
distinct organizations
Tax years
2018–2024
6 filings in the corpus
Approved for future payment
$5,860,623
32 commitments · not included in grants paid
By tax year
| Tax year | Grants paid | Amount paid | Approved for future |
|---|---|---|---|
| 2018 | 3 | $491,807 | $1,022,275 |
| 2020 | 9 | $1,988,946 | $374,118 |
| 2021 | 8 | $1,578,663 | $400,435 |
| 2022 | 4 | $525,191 | $1,347,728 |
| 2023 | 9 | $1,143,767 | $1,215,708 |
| 2024 | 14 | $1,581,155 | $1,500,359 |
Top recipients
The 18 recipients receiving the most from Rosenau Family Research Foundation, by grants paid, out of 18 distinct recipients.
| Recipient | Match | Location | Grants | Total paid | Latest year |
|---|---|---|---|---|---|
| University of Illinois | U | Chicago, IL | 16 | $1,694,999 | 2024 |
| Children's Hospital of Pittsburgh 25-1865744 | C | Pittsburgh, PA | 3 | $1,224,236 | 2021 |
| University of Pittsburgh | U | Pittsburgh, PA | 3 | $1,068,401 | 2024 |
| University of Buffalo 16-0865182 | D | Amherst, NY | 5 | $833,817 | 2024 |
| Biomedical Research Institute of Nj 46-0625176 | C | Cedar Knools, NJ | 5 | $657,292 | 2024 |
| Children's Hospital of Chicago 36-3357004 | D | Chicago, IL | 1 | $400,000 | 2023 |
| Duke University 56-0532129 | C | Durham, NC | 1 | $250,000 | 2024 |
| University of Wisconsin | U | Madison, WI | 1 | $244,126 | 2018 |
| University of Connecticut Health Ce | U | Farmington, CT | 2 | $192,999 | 2024 |
| Thomas Jefferson University 23-1352651 | B | Philadelphia, PA | 1 | $125,707 | 2018 |
| University of Minnesota | U | Minneapolis, MN | 1 | $125,000 | 2024 |
| Nationwide Children's Hospital 01-0782751 | C | Columbus, OH | 1 | $125,000 | 2024 |
| University of Pennsylvania | U | Philadelphia, PA | 2 | $120,000 | 2024 |
| University of Minnesota Medical Sch | U | Minneapolis, MN | 1 | $105,000 | 2020 |
| University of Kansas | U | Kansas City, KS | 1 | $59,593 | 2024 |
| Mayo Clinic | U | Rochester, MN | 1 | $57,359 | 2024 |
| University of Florida | U | Gainesville, FL | 1 | $21,000 | 2020 |
| Emory University | U | Atlanta, GA | 1 | $5,000 | 2021 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Every grant
All 79 grant rows this organization reported, most recent first.
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2024 | Nationwide Children's Hospital Columbus, OH | C | $250,000 | approved, future | Evaluation of In Utero Gene Therapy in Canine KD | 202502809349101005 |
| 2024 | University of Pittsburgh Pittsburgh, PA | U | $250,000 | approved, future | Disclosure of Newborn Screening Results for KD in Pennsylvania | 202502809349101005 |
| 2024 | Duke University Durham, NC | C | $250,000 | paid | Immune Responses in Peripheral Nerves after Hematopoietic Stem Cell Transplants for KD | 202502809349101005 |
| 2024 | UW Department of Pediatrics Madison, WI | U | $250,000 | approved, future | Enriching CF Newborn Screening Outcomes Through a Precision Personalized Medicine Strategy | 202502809349101005 |
| 2024 | University of Minnesota Minneapolis, MN | U | $235,000 | approved, future | GenoKrabbe: A Comprehensive Genotype-Phenotype Database for KD | 202502809349101005 |
| 2024 | University of Connecticut Health Ce Farmington, CT | U | $175,049 | paid | Evaluation of Immunomodulatory Therapy for the Treatment of KD | 202502809349101005 |
| 2024 | Biomedical Research Institute of Nj Cedar Knools, NJ | C | $149,154 | paid | Psychosine Profiling and Evaluation as a Therapeutic for KD | 202502809349101005 |
| 2024 | University of Minnesota Minneapolis, MN | U | $125,000 | paid | GenoKrabbe: A Comprehensive Genotype-Phenotype Database for KD | 202502809349101005 |
| 2024 | University of Illinois Chicago, IL | U | $125,000 | approved, future | A Maladaptive Pathway Involved In Early Pathogenesis of KD | 202502809349101005 |
| 2024 | University of Illinois Chicago, IL | U | $125,000 | paid | A Maladaptive Pathway Involved In Early Pathogenesis of KD | 202502809349101005 |
| 2024 | University of Buffalo Amherst, NY | D | $125,000 | approved, future | Modulating Oligodendroglial NFkB as a Therapeutic Strategy for KD | 202502809349101005 |
| 2024 | University of Pittsburgh Pittsburgh, PA | U | $125,000 | paid | Disclosure of Newborn Screening Results for KD in Pennsylvania | 202502809349101005 |
| 2024 | Nationwide Children's Hospital Columbus, OH | C | $125,000 | paid | Evaluation of In Utero Gene Therapy in Canine KD | 202502809349101005 |
| 2024 | University of Buffalo Amherst, NY | D | $125,000 | paid | Modulating Oligodendroglial NFkB as a Therapeutic Strategy for KD | 202502809349101005 |
| 2024 | Duke University Durham, NC | C | $125,000 | approved, future | Immune Responses in Peripheral Nerves after Hematopoietic Stem Cell Transplants for KD | 202502809349101005 |
| 2024 | University of Illinois Chicago, IL | U | $85,000 | approved, future | Challenging the Capacity of AAV-GALC Gene Therapy to Cope with Modifiers of Adult Brain Function | 202502809349101005 |
| 2024 | University of Illinois Chicago, IL | U | $85,000 | paid | Challenging the Capacity of AAV-GALC Gene Therapy to Cope with Modifiers of Adult Brain Function | 202502809349101005 |
| 2024 | University of Pennsylvania Philadelphia, PA | U | $60,000 | paid | Elucidating the Mechanisms Underlying Macrophage Dysfunction in KD | 202502809349101005 |
| 2024 | University of Illinois Chicago, IL | U | $60,000 | paid | Effects of Motor Learning on Efficacy and Safety of AAV-Gene Therapy in KD | 202502809349101005 |
| 2024 | University of Illinois Chicago, IL | U | $60,000 | paid | Dysfunction of Brain Synapsis in KD | 202502809349101005 |
| 2024 | University of Kansas Kansas City, KS | U | $59,593 | paid | Improving Developmental Outcomes in Mouse Models of KD | 202502809349101005 |
| 2024 | Mayo Clinic Rochester, MN | U | $57,359 | paid | Elucidating the Metabolic Signature of KD Plasma, Dried Blood Spots, and Cerebrospinal Fluid Using Flux Analysis | 202502809349101005 |
| 2024 | Mayo Clinic Rochester, MN | U | $55,359 | approved, future | Elucidating the Metabolic Signature of KD Plasma, Dried Blood Spots, and Cerebrospinal Fluid Using Flux Analysis | 202502809349101005 |
| 2023 | Children's Hospital of Chicago Chicago, IL | D | $400,000 | paid | Caregiver and Clinician Awareness for Early CF | 202402619349100410 |
| 2023 | Duke University Durham, NC | C | $375,000 | approved, future | Improving KD Family Experience Through Communication and Promoting | 202402619349100410 |
| 2023 | University of Illinois Chicago, IL | U | $250,000 | approved, future | Immune Responses in Peripheral Nerves after Hematopoietic Stem Cell Transplants for KD | 202402619349100410 |
| 2023 | University of Buffalo Amherst, NY | D | $205,983 | paid | Innovative Model Systems to Study & Boost Innate Immunity in KD | 202402619349100410 |
| 2023 | University of Illinois Chicago, IL | U | $170,000 | approved, future | Challenging the Capacity of AAV-GALC Gene Therapy to Cope with Modifiers of Adult Brain Function | 202402619349100410 |
| 2023 | Biomedical Research Institute of Nj Cedar Knools, NJ | C | $149,154 | approved, future | Psychosine Profiling and Evaluation as a Therapeutic for KD | 202402619349100410 |
| 2023 | Biomedical Research Institute of Nj Cedar Knools, NJ | C | $129,834 | paid | Psychosine Profiling and Evaluation as a Therapeutic for KD | 202402619349100410 |
| 2023 | University of Illinois Chicago, IL | U | $125,000 | paid | Immune Responses in Peripheral Nerves after Hematopoietic Stem Cell Transplants for KD | 202402619349100410 |
| 2023 | University of Illinois Chicago, IL | U | $85,000 | paid | Challenging the Capacity of AAV-GALC Gene Therapy to Cope with Modifiers of Adult Brain Function | 202402619349100410 |
| 2023 | University of Cennecticut Health Ce Farmington, CT | U | $63,342 | approved, future | Evaluation of Immunomodulatory Therapy for the Treatment of KD | 202402619349100410 |
| 2023 | University of Illinois Chicago, IL | U | $60,000 | approved, future | Effects of Motor Learning on Efficacy and Safety of AAV-Gene Therapy in KD | 202402619349100410 |
| 2023 | University of Illinois Chicago, IL | U | $60,000 | approved, future | Dysfunction of Brain Synapsis in KD | 202402619349100410 |
| 2023 | University of Illinois Chicago, IL | U | $60,000 | paid | Dysfunction of Brain Synapsis in KD | 202402619349100410 |
| 2023 | University of Pennsylvania Philadelphia, PA | U | $60,000 | paid | Elucidating the Mechanisms Underlying Macrophage Dysfunction in KD | 202402619349100410 |
| 2023 | University of Illinois Chicago, IL | U | $60,000 | paid | Effects of Motor Learning on Efficacy and Safety of AAV-Gene Therapy in KD | 202402619349100410 |
| 2023 | University of Pennsylvania Philadelphia, PA | U | $60,000 | approved, future | Elucidating the Mechanisms Underlying Macrophage Dysfunction in KD | 202402619349100410 |
| 2023 | University of Kansas Kansas City, KS | U | $28,212 | approved, future | Improving Developmental Outcomes in Mouse Models of KD | 202402619349100410 |
| 2023 | University of Connecticut Health Ce Farmington, CT | U | $17,950 | paid | Evaluation of Immunomodulatory Therapy for the Treatment of KD | 202402619349100410 |
| 2022 | Children's Hospital of Chicago Chicago, IL | D | $400,000 | approved, future | Caregiver and Clinician Awareness for Early CF | 202312569349101016 |
| 2022 | University of Connecticut Health Ce Farmington, CT | U | $381,589 | approved, future | Evaluation of Immunomodulatory Therapy for the Treatment of KD | 202312569349101016 |
| 2022 | Biomedical Research Institute of Nj Cedar Knools, NJ | C | $278,988 | approved, future | Psychosine Profiling and Evaluation as a Therapeutic for KD | 202312569349101016 |
| 2022 | University of Buffalo Amherst, NY | D | $205,983 | approved, future | Innovative Model Systems to Study & Boost Innate Immunity in KD | 202312569349101016 |
| 2022 | University of Buffalo Amherst, NY | D | $183,012 | paid | Infrastructure Support of KD & Myelin Research | 202312569349101016 |
| 2022 | University of Illinois Chicago, IL | U | $142,423 | paid | Vesicular Delivery of GALC for ERT of KD | 202312569349101016 |
| 2022 | Biomedical Research Institute of Nj Cedar Knools, NJ | C | $124,756 | paid | Psychosine Profiling and Evaluation as a Therapeutic for KD | 202312569349101016 |
| 2022 | Children's Hospital of Philadelphia Philadelphia, PA | B | $81,168 | approved, future | Improving KD Family Experience Through Communication and Promoting | 202312569349101016 |
| 2022 | University of Illinois Chicago, IL | U | $75,000 | paid | Generation of KD Mouse Model to Enable Regulated Expression of Therapeutic GALC Enzyme | 202312569349101016 |
| 2021 | Children's Hospital of Pittsburgh Pittsburgh, PA | C | $476,000 | paid | Escolar's Grant "NDRD - KD Patient Care & Research" | 202201369349105335 |
| 2021 | Children's Hospital of Pittsburgh Pittsburgh, PA | C | $374,118 | paid | Escolar's Grant "NDRD - KD Patient Care & Research" | 202201369349105335 |
| 2021 | University of Buffalo Amherst, NY | D | $198,156 | paid | Infrastructure Support of KD & Myelin Research | 202201369349105335 |
| 2021 | University of Buffalo Amherst, NY | D | $183,012 | approved, future | Infrastructure Support of KD & Myelin Research | 202201369349105335 |
| 2021 | University of Illinois Chicago, IL | U | $180,000 | paid | Studies of GALC Correction Stability After AAV Gene Therapy for KD Grant | 202201369349105335 |
| 2021 | University of Illinois Chicago, IL | U | $148,723 | paid | Vesicular Delivery of GALC for ERT of KD | 202201369349105335 |
| 2021 | University of Illinois Chicago, IL | U | $142,423 | approved, future | Vesicular Delivery of GALC for ERT of KD | 202201369349105335 |
| 2021 | University of Buffalo Amherst, NY | D | $121,666 | paid | Innovative Model Systems to Study & Boost Innate Immunity in KD | 202201369349105335 |
| 2021 | University of Illinois Chicago, IL | U | $75,000 | approved, future | Generation of KD Mouse Model to Enable Regulated Expression of Therapeutic GALC Enzyme | 202201369349105335 |
| 2021 | University of Illinois Chicago, IL | U | $75,000 | paid | Generation of KD Mouse Model to Enable Regulated Expression of Therapeutic GALC Enzyme | 202201369349105335 |
| 2021 | Emory University Atlanta, GA | U | $5,000 | paid | Paul M Fernhoff Lecture Series Grant | 202201369349105335 |
| 2020 | University of Pittsburgh Pittsburgh, PA | U | $500,000 | paid | Escolar's Grant "Treatment of KD Using Gene Therapy: Continuation" | 202133149349100018 |
| 2020 | University of Pittsburgh Pittsburgh, PA | U | $443,401 | paid | Escolar's Grant "Treatment of KD Using Gene Therapy: Continuation" | 202133149349100018 |
| 2020 | Children's Hospital of Pittsburgh Pittsburgh, PA | C | $374,118 | approved, future | Escolar's Grant "NDRD - KD Patient Care & Research" | 202133149349100018 |
| 2020 | Children's Hospital of Pittsburgh Pittsburgh, PA | C | $374,118 | paid | Escolar's Grant "NDRD - KD Patient Care & Research" | 202133149349100018 |
| 2020 | University of Illinois Chicago, IL | U | $180,000 | paid | Studies of GALC Correction Stability After AAV Gene Therapy for KD Grant | 202133149349100018 |
| 2020 | University of Illinois Chicago, IL | U | $158,853 | paid | Vesicular Delivery of GALC for ERT of KD | 202133149349100018 |
| 2020 | Biomedical Research Institute of Nj Morristown, NJ | D | $131,574 | paid | Development of Pharmacological Chaperone Therapy for KD Grant | 202133149349100018 |
| 2020 | University of Minnesota Medical Sch Minneapolis, MN | U | $105,000 | paid | Brain Connectome as a Novel Biomarker of KD | 202133149349100018 |
| 2020 | University of Illinois Chicago, IL | U | $75,000 | paid | Generation of KD Mouse Model to Enable Regulated Expression of Therapeutic GALC Enzyme | 202133149349100018 |
| 2020 | University of Florida Gainesville, FL | U | $21,000 | paid | Developing a Target-Assay for Substrate Reduction Agents for KD Grant | 202133149349100018 |
| 2018 | Children's Hopsital of Pittsburgh Pittsburgh, PA | U | $377,269 | approved, future | RESEARCH TO BETTER TREAT KD - NDRD | 201931359349103913 |
| 2018 | University of Wisconsin Madison, WI | U | $245,459 | approved, future | RESEARCH FOR WHOLE GENOME SEQUENCING | 201931359349103913 |
| 2018 | University of Wisconsin Madison, WI | U | $244,126 | paid | RESEARCH FOR WHOLE GENOME SEQUENCING | 201931359349103913 |
| 2018 | Biomedical Research Institute of Nj Morristown, NJ | D | $140,024 | approved, future | PHARMACOLOGICAL CHAPERONE THERAPY | 201931359349103913 |
| 2018 | Biomedical Research Institute of Nj Morristown, NJ | D | $131,574 | approved, future | PHARMACOLOGICAL CHAPERONE THERAPY | 201931359349103913 |
| 2018 | Thomas Jefferson University Philadelphia, PA | B | $127,949 | approved, future | MOUSE MODEL TRANSLATION INTO HUMAN | 201931359349103913 |
| 2018 | Thomas Jefferson University Philadelphia, PA | B | $125,707 | paid | MOUSE MODEL TRANSLATION INTO HUMAN | 201931359349103913 |
| 2018 | Biomedical Research Institute of Nj Morristown, NJ | D | $121,974 | paid | PHARMACOLOGICAL CHAPERONE THERAPY | 201931359349103913 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Source filings
Every figure above is traceable to one of these IRS e-file returns by its OBJECT_ID.
| Form | Tax year | Period end | Filed | Schema | IRS OBJECT_ID |
|---|---|---|---|---|---|
| 990PF | 2024 | 2024-12-31 | not stated | 2024v5.2 | 202502809349101005 |
| 990PF | 2023 | 2023-12-31 | not stated | 2023v5.1 | 202402619349100410 |
| 990PF | 2022 | 2022-12-31 | not stated | 2022v5.0 | 202312569349101016 |
| 990PF | 2021 | 2021-12-31 | not stated | 2021v4.0 | 202201369349105335 |
| 990PF | 2020 | 2020-12-31 | not stated | 2020v4.0 | 202133149349100018 |
| 990PF | 2018 | 2018-12-31 | not stated | 2018v3.1 | 201931359349103913 |
Derived from IRS Form 990-PF e-file XML; recipient identities from the IRS Exempt Organizations Business Master File. Dataset version 2026.09.0, built 2026-09-03. The same rows as Parquet: manifest; as JSON: /api/funders/263070514.json.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.